| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 10833 | 2011 |
| Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 9273 | 2001 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 6579 | 2005 |
| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 6492 | 2018 |
| Defining the clinical course of multiple sclerosis: results of an international survey FD Lublin, SC Reingold, ... Neurology 46 (4), 907-911, 1996 | 4995 | 1996 |
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ... New England Journal of Medicine 354 (9), 899-910, 2006 | 4001 | 2006 |
| Defining the clinical course of multiple sclerosis The 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 3676 | 2014 |
| Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial IFNB Multiple Sclerosis Study Group Neurology 43 (4), 655-655, 1993 | 2853 | 1993 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 1877 | 2017 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 1777 | 2017 |
| Natalizumab plus interferon beta-1a for relapsing multiple sclerosis RA Rudick, WH Stuart, PA Calabresi, C Confavreux, SL Galetta, ... New England Journal of Medicine 354 (9), 911-923, 2006 | 1706 | 2006 |
| Development of a multiple sclerosis functional composite as a clinical trial outcome measure GR Cutter, ML Baier, RA Rudick, DL Cookfair, JS Fischer, J Petkau, ... Brain 122 (5), 871-882, 1999 | 1418 | 1999 |
| Disease modifying therapies in multiple sclerosis DS Goodin, EM Frohman, GP Garmany, J Halper, WH Likosky, FD Lublin Neurology 58 (2), 169-78, 2002 | 1098 | 2002 |
| Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ... Multiple Sclerosis Journal 14 (9), 1157-1174, 2008 | 922 | 2008 |
| Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, AT Reder, ... The Lancet Neurology 13 (6), 545-556, 2014 | 895 | 2014 |
| Interferon beta‐lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial IFNB Multiple Sclerosis Study Group and the University of British Columbia ... Neurology 45 (7), 1277-1285, 1995 | 595 | 1995 |
| Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing … E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ... The Lancet Neurology 8 (3), 254-260, 2009 | 588 | 2009 |
| Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial BAC Cree, JL Bennett, HJ Kim, BG Weinshenker, SJ Pittock, ... The Lancet 394 (10206), 1352-1363, 2019 | 549 | 2019 |
| Effect of relapses on development of residual deficit in multiple sclerosis FD Lublin, M Baier, G Cutter Neurology 61 (11), 1528-1532, 2003 | 548 | 2003 |
| Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis DH Miller, PS Albert, F Barkhof, G Francis, JA Frank, S Hodgkinson, ... Annals of neurology 39 (1), 6-16, 1996 | 542 | 1996 |
